SENSEX
NIFTY
GOLD
USD/INR

Weather

image 35    C

Economy News

The Economic Times

Economy / The Economic Times

details

AstraZeneca 'magic' faces rare test after trial failure, share slide

AstraZeneca's nerve drug Wainua unexpectedly failed a late-stage heart disease trial. This setback has caused investor concern and impacted the company's share price. Investors now await results from two key oncology trials, SERENA-4 and AVANZAR. Success in these trials is crucial for maintaining confidence in AstraZeneca's research engine. The company aims for significant revenue growth by 2030 through new drug launches.

24 Jul 2026 11:56 am